Navigation Links
RI Hospital researchers identify components in C. diff that may lead to better treatment
Date:1/30/2014

PROVIDENCE, R.I. Rhode Island Hospital researchers have identified components in Clostridium difficile (C. diff) that may lead to new diagnostic tools, and ultimately more timely and effective treatment for this often fatal infection. C. diff is a spore-forming bacterium that causes severe diarrhea and is responsible for 14,000 deaths annually in the U.S. The study is published online in advance of print in the Journal of Molecular Diagnostics.

In this study, researchers identified components of the C. diff bacteria that can be used to develop a rapid diagnostic test to determine if a patient with a diarrheal illness has C. diff infection and, if so, if the infection is due to a hypervirulent strain of this bacterium. Such a determination may lead to more rapid initiation of appropriate antibiotics in infected patients with the hope of improving their outcome.

"C. difficle can be a life-threatening infection," said Leonard Mermel, D.O., medical director of the department of epidemiology and infection control at Rhode Island Hospital. "We believe that rapid identification of this bacterium will assist in timely initiation of antimicrobial therapy and admission to a setting where the patient is more appropriately observed based on his or her signs, symptoms and strain of bacteria causing the infection."

The technology revealed in this study can be integrated as a point-of-care device to help quickly detect and identify C. diff strains that pose significant health threats in hospitals and other health care settings.

According to the Centers for Disease Control and Prevention, the most serious C. diff cases are in the elderly and individuals with certain medical problems. C. diff spores can live outside the human body and may be transferred to bed linens, bed rails, bathroom fixtures and medical equipment, and other areas in the infected person's environment.

The incidence of C. diff has been on the rise and is increasing in severity and mortality in the U.S. and Europe. The cost of treating C. diff in the U.S. in 2008 topped $4 billion; and in 2006-07 it was responsible for an estimated 14,000 deaths in the U.S.

"With the emergence of a more severe C. diff strain (NAP1/027/B1), there is an urgent need for a highly sensitive and rapid method of detection and strain typing," Mermel said.

Current methods of diagnosing C. diff include stool cultures, toxin testing, enzyme immunoassays and polymerase chain reaction. While often effective, they may be impractical for use in an urgent care setting or emergency department where patients are presenting with gastrointestinal symptoms "The assay we have developed has the potential to quickly and accurately indicate the presence of specific markers of certain hypervirulent strains of C. diff," Mermel said. "We're confident this will lead to more timely, accurate diagnosis and treatment, with the hope that fewer patients will develop serious complications from this infection."


'/>"/>

Contact: Ellen Slingsby
eslingsby@lifespan.org
401-444-6421
Lifespan
Source:Eurekalert

Related medicine news :

1. Higher-spending hospitals have fewer deaths for emergency patients
2. Predictors identified for rehospitalization among post-acute stroke patients
3. More Smog Might Mean More Hospitalizations
4. After Hospitalization, Men More Likely to Show Up in ER
5. Choosing the right hospital may save your babys life
6. Heart Attack Survival Varies Widely Among Hospitals, Study Finds
7. In Some Brain Bleeds, Patients Do Better at High-Volume Hospitals
8. Rate of Hospitalizations for Stroke Has Declined in U.S.
9. Hospital readmission rates linked to availability of care, socioeconomics
10. Availability of Beds, Poverty Drive Costly Hospital Readmissions
11. Inhaled Steroids Lead to Big Drop in Asthma Deaths at Texas Hospital: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... York, NY (PRWEB) , ... April 28, 2017 ... ... Medical Laboratory to expanded distribution of the GlycoMark test throughout the Northeast U.S. ... recent hyperglycemia in patients with diabetes. The GlycoMark test provides a clinically proven ...
(Date:4/28/2017)... ... April 28, 2017 , ... The Radiology Business Management Association (RBMA) ... The annual board election process has been in place since the RBMA was founded ... Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, MHA, CMM, FRBMA, as president. Dr. Dickerson the ...
(Date:4/28/2017)... Texas (PRWEB) , ... April 28, 2017 , ... The ... plaque in recently to the labor and delivery team at Women’s Hospital at Renaissance ... mothers who give birth at the hospital and decide to donate. , “Women’s ...
(Date:4/28/2017)... ... April 28, 2017 , ... People are starting to accept that hearing ... aid doesn’t have the stigma it had when great-grandpa wore his hearing aids years ... in a NALA North American Speaker Series (NASS) segment. “He probably wore ...
(Date:4/28/2017)... ... April 28, 2017 , ... Researchers at ... of ActiGraph’s CentrePoint Data Hub in a sample of participants enrolled ... wearable activity and sleep monitoring solutions for the global scientific community. The company’s ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Research and Markets has announced the addition ... Addressing Production Complexities Through Risk Management and Quality by ... ... Market Prospects: Overcoming Production Complexities Through Risk Management and ... current trends in the global biosimilars market, with a ...
(Date:4/20/2017)... Research and Markets has announced the addition ... Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics during ... ... rise from USD 20 Billion in 2015 to around USD 26 ... - Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage ...
(Date:4/20/2017)... Inc ., a digital health company focused on modernizing and ... $25 million in Series B funding led by Qiming US ... Seattle that is part of a broader family ... included participation from SR One , who led ZappRx,s ... Google Ventures). As part of the financing, Mark McDade ...
Breaking Medicine Technology: